看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。4 A, Y9 {+ U7 [
: q8 S$ X& J6 H' C! u, n3 ]1 K; X* [7 W
Currently available feasibility data for possible combination strategies. ' j8 E. q1 f7 Y# G8 `
————————————————————————————————
- z8 v! y. E* l! [& d8 S0 s* vCombination Feasibility according to preliminary data 0 t6 K; f* z' o& b! p: r
——————————————————————————————————
P5 j# o$ p: Q1 W* jBevacizumab + sorafenib Yes, reduced dose
0 [$ t' j5 x2 @" y, YBevacizumab + sunitinib† No 9 o M$ M! x/ K7 B
Bevacizumab + temsirolimus Yes
, e+ v( O, ]1 L; k8 m; G) `Bevacizumab + everolimus Yes : G, ^5 B! n; C; @2 b5 t Y" Z( ]
Sorafenib + sunitinib ? " _, c4 @% g7 ]" M
Sorafenib + temsirolimus Yes, reduced dose 6 n. W8 V& i$ m- \. p/ _( E
Sorafenib + everolimus Yes, reduced dose
1 W6 s+ `& ~4 c$ q' m/ lSunitinib + temsirolimus† No $ B( y% |& [" W* Y! u7 g1 [1 n( m
Sunitinib + everolimus ?
" H/ }' J$ L( l5 e7 R7 k4 U" hTemsirolimus + everolimus ?
2 x7 M/ i8 g& [& n————————————————————
. ~; |3 `4 j" w. J5 B( f' v! i; t†Led to US FDA warning. B) K: Q! p" p; c
?: As yet unattempted combination.6 v' O8 {8 v2 a1 L% E! H
|